BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
Source: SeekingAlpha
2025-08-06 07:52:27 ET
More on BeOne Medicines
- BeOne Medicines: Competitive Advantage Of Zanubrutinib In The CLL Field
- BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
- BeiGene Q2 2025 Earnings Preview
- BeOne Medicines' Tevimbra gets CHMP endorsement
- Seeking Alpha’s Quant Rating on BeiGene
Read the full article on Seeking Alpha
For further details see:
BeOne Medicines beats top-line and bottom-line estimates; updates FY guidance
BeiGene
NASDAQ: BEIGF
BEIGF Trading
0.0% G/L:
$23.75 Last:
100 Volume:
$23.75 Open:
BEIGF Latest News
BEIGF Stock Data
$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel
